Table 9Efficacy of iloperidone in short-term trials

Study N, durationChange from baseline in PANSS total score
ILP3004ST
N=616, 6 weeks
Iloperidone 4–8 mg −9.5, P=0.017a
Iloperidone 10–16 mg −11.1, P=0.002
Risperidone 4–8 mg −16.6, P=0.001
Placebo −3.5
ILP30005ST
N=706, 6 weeks
Iloperidone 12–16 mg −11.0, P=0.101
Iloperidone 20–24 mg −14.0, P=0.005
Risperidone: 6–8 mg −18.8, P<0.001
Placebo −7.6
Cutler 2008
N=606, 4 weeks
Iloperidone 24 mg −12.0, P<0.01
Ziprasidone 160 mg −12.3, P<0.05
Placebo −7.1
a

All P values were compared with placebo.

From: Results

Cover of Drug Class Review: Atypical Antipsychotic Drugs
Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet].
McDonagh M, Peterson K, Carson S, et al.
Portland (OR): Oregon Health & Science University; 2010 Jul.
Copyright © 2010 by Oregon Health & Science University, Portland, Oregon 97239. All rights reserved.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.